- Q2 average monetizable daily active usage (mDAU) was 237.8 million, up 16.6% compared to Q2 of the prior year. The increase was driven by ongoing product improvements and global conversation around current events.
- Average US mDAU was 41.5 million for Q2, up 14.7% compared to Q2 of the prior year.
- Average international mDAU was 196.3 million for Q2, up 17.0% compared to Q2 of the prior year.
Elicio Therapeutics To Present Updated Clinical T Cell And Antigen Spreading Response Data From The Ongoing AMPLIFY-201 Phase 1 Study Of ELI-002 And Preclinical Data On ELI-007 And ELI-008 At The AACR Annual Meeting
68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells 84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cellsThe majority of ELI-002-treated patients
